International Clinical Trial: A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07456046) titled 'A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation' on March 3.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: D3 Bio (Wuxi) Co., Ltd

Condition: KRAS P.G12D

Intervention: Drug: D3S-003

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 31, 2026

Target Sample Size: 42

To know more, visit https://clinicaltrials.gov/study/NCT07456046

Published by HT Digital Content Services with permissi...